SG11201900090TA - Treatment of cancer - Google Patents
Treatment of cancerInfo
- Publication number
- SG11201900090TA SG11201900090TA SG11201900090TA SG11201900090TA SG11201900090TA SG 11201900090T A SG11201900090T A SG 11201900090TA SG 11201900090T A SG11201900090T A SG 11201900090TA SG 11201900090T A SG11201900090T A SG 11201900090TA SG 11201900090T A SG11201900090T A SG 11201900090TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- california
- rule
- treatment
- applicant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization 1#11101111 0 11101 HOE 3E1 0 0111111 0111 OM 11011101 IMO 1111 HE International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\"1 WO 2018/013862 Al 18 January 2018 (18.01.2018) W I PO I PC T (51) International Patent Classification: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, A61K 31/52 (2006.01) C07D 487/04 (2006.01) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (21) International Application Number: HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, PCT/US2017/042011 KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (22) International Filing Date: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 13 July 2017 (13.07.2017) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, 62/362,369 14 July 2016 (14.07.2016) US UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (71) Applicant: MINGSIGHT PHARMACEUTICALS, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, INC. [US/US]; P.O. Box 261208, San Diego, California MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 92196 (US). TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (72) Inventors: NIESMAN, Michael; P.O. Box 261208, San KM, ML, MR, NE, SN, TD, TG). Diego, California 92196 (US). ZHANG, Kai; P.O. Box 261208, San Diego, California 92196 (US). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a (74) Agent: FLOYD, Jennifer; Wilson Sonsini Goodrich & Ro- sait, 650 Page Mill Road, Palo Alto, California 94304 (US). — = as to the applicant's entitlement to claim the priority of the patent (Rule 4.17(0 _ Designated States (unless otherwise indicated, for every earlier application (Rule 4.17(iii)) _ (81) kind of national protection available): AE, AG, AL, AM, = _ AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, _ = Title: TREATMENT OF CANCER = (54) = Cell Proliferation cmpd A plus Ibrutinib = —o— —•— 1.25 nM — o — Cmpd A only = 0.3125 nM —0—.625 nM = 120% ,, --- = 0 110% U = = 48 oill11111111111 -112 `• BO% . Q' i i I 1 11 I I I I i • I I , , . J = = _ = 60% --- ji lk lvi = a) 40% 20% — 0_ c.) —......w.m r--- \"• 111 + 4 -...1 1 1.11 ,* Ill • • - 0 0% 0.01 0.10 1.00 N Cm pd A Drug Concentration (OA) GC en ,—, © FIG. 3C 00 1-1 (57) : Provided herein are compositions and methods for the treatment of a hematological malignancy. Also disclosed herein C:::: ) are compositions and methods for the treatment of Ewings Sarcoma. Said compositions comprise isoform selective pyrrolo-pyrazole el PKC inhibitors. C [Continued on next page] WO 2018/013862 Al MIDEDIMOM0101011EFIENIIEMIDERIEDIDIIIMEHOIS Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event amendments (Rule 48.2(h)) of receipt of
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662362369P | 2016-07-14 | 2016-07-14 | |
PCT/US2017/042011 WO2018013862A1 (en) | 2016-07-14 | 2017-07-13 | Treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201900090TA true SG11201900090TA (en) | 2019-02-27 |
Family
ID=60953395
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201900090TA SG11201900090TA (en) | 2016-07-14 | 2017-07-13 | Treatment of cancer |
Country Status (8)
Country | Link |
---|---|
US (5) | US11154555B2 (en) |
EP (1) | EP3484477B1 (en) |
JP (3) | JP2019524700A (en) |
CN (2) | CN109715166A (en) |
AU (3) | AU2017295858A1 (en) |
CA (1) | CA3030429A1 (en) |
SG (1) | SG11201900090TA (en) |
WO (1) | WO2018013862A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2016355303B2 (en) * | 2015-11-20 | 2021-10-07 | Mingsight Pharmaceuticals, Inc. | Treatment of autoimmune disease |
EP3484477B1 (en) | 2016-07-14 | 2023-09-13 | Mingsight Pharmaceuticals, Inc. | Treatment of cancer |
EP4068967A4 (en) * | 2019-12-06 | 2023-12-27 | Mingsight Pharmaceuticals, Inc. | Compositions comprising pkc-beta inhibitors and processes for the preparation thereof |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7786213B2 (en) | 2003-10-15 | 2010-08-31 | The Regents Of The University Of California | Biomacromolecule polymer conjugates |
CA2658263A1 (en) * | 2006-07-18 | 2008-01-24 | University Of Rochester | Thiadiazolidinone derivatives |
UA96618C2 (en) * | 2007-02-07 | 2011-11-25 | Пфайзер Инк. | 3-amino-pyrrolo[3,4-c] pyrazole- 5 (1h, 4h, 6h) carbaldehyde derivatives as pkc inhibitors |
KR101060892B1 (en) * | 2007-02-07 | 2011-08-31 | 화이자 인코포레이티드 | 3-amino-pyrrolo [3,4-C] pyrazole-5 (1H, 4H, 6H) carbaldehyde derivatives as PPC inhibitors |
WO2008125945A2 (en) | 2007-04-12 | 2008-10-23 | Pfizer Inc. | 3-amido-pyrrolo [3, 4-c] pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as inhibitors of protein kinase c |
WO2011120911A1 (en) | 2010-03-30 | 2011-10-06 | Novartis Ag | Pkc inhibitors for the treatment of b-cell lymphoma having chronic active b-cell-receptor signalling |
EP2906556A1 (en) * | 2012-10-11 | 2015-08-19 | Pharmacyclics, Inc. | Companion diagnostics for tec family kinase inhibitor therapy |
EP2983670A4 (en) | 2013-04-08 | 2017-03-08 | Pharmacyclics LLC | Ibrutinib combination therapy |
WO2015110923A2 (en) | 2014-01-21 | 2015-07-30 | Acerta Pharma B.V. | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor |
EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
US9416131B2 (en) | 2014-03-25 | 2016-08-16 | Ono Pharmaceutical Co., Ltd. | Prophylactic agent and/or therapeutic agent for diffuse large B-cell lymphoma |
ES2872338T3 (en) | 2014-05-23 | 2021-11-02 | Mingsight Pharmaceuticals Inc | Treatment of autoimmune diseases |
JO3589B1 (en) | 2014-08-06 | 2020-07-05 | Novartis Ag | Protein kinase c inhibitors and methods of their use |
WO2016100882A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Combination therapies |
EP3484477B1 (en) * | 2016-07-14 | 2023-09-13 | Mingsight Pharmaceuticals, Inc. | Treatment of cancer |
CN112118842A (en) | 2018-01-17 | 2020-12-22 | 明赛制药股份公司 | Combination therapy for cancer treatment |
-
2017
- 2017-07-13 EP EP17828498.0A patent/EP3484477B1/en active Active
- 2017-07-13 US US16/317,520 patent/US11154555B2/en active Active
- 2017-07-13 CA CA3030429A patent/CA3030429A1/en active Pending
- 2017-07-13 JP JP2019500242A patent/JP2019524700A/en not_active Withdrawn
- 2017-07-13 SG SG11201900090TA patent/SG11201900090TA/en unknown
- 2017-07-13 CN CN201780056643.XA patent/CN109715166A/en active Pending
- 2017-07-13 AU AU2017295858A patent/AU2017295858A1/en not_active Abandoned
- 2017-07-13 WO PCT/US2017/042011 patent/WO2018013862A1/en unknown
- 2017-07-13 CN CN202210728932.2A patent/CN115381832A/en active Pending
-
2021
- 2021-09-08 US US17/469,715 patent/US20220000870A1/en not_active Abandoned
- 2021-09-08 US US17/469,551 patent/US20210401837A1/en active Pending
- 2021-09-10 US US17/472,130 patent/US20220202814A1/en not_active Abandoned
- 2021-09-10 US US17/472,544 patent/US20220202815A1/en not_active Abandoned
-
2022
- 2022-03-11 AU AU2022201717A patent/AU2022201717B2/en active Active
- 2022-08-04 JP JP2022125000A patent/JP2022169593A/en not_active Withdrawn
-
2023
- 2023-02-22 JP JP2023026651A patent/JP2023075161A/en not_active Withdrawn
- 2023-09-25 AU AU2023237034A patent/AU2023237034A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20190216809A1 (en) | 2019-07-18 |
CA3030429A1 (en) | 2018-01-18 |
EP3484477B1 (en) | 2023-09-13 |
AU2017295858A1 (en) | 2019-01-24 |
US20220202814A1 (en) | 2022-06-30 |
US20220000870A1 (en) | 2022-01-06 |
AU2022201717B2 (en) | 2023-07-27 |
JP2022169593A (en) | 2022-11-09 |
WO2018013862A1 (en) | 2018-01-18 |
CN115381832A (en) | 2022-11-25 |
AU2023237034A1 (en) | 2023-10-12 |
JP2023075161A (en) | 2023-05-30 |
AU2022201717A1 (en) | 2022-04-07 |
JP2019524700A (en) | 2019-09-05 |
EP3484477A1 (en) | 2019-05-22 |
EP3484477A4 (en) | 2020-03-04 |
CN109715166A (en) | 2019-05-03 |
US11154555B2 (en) | 2021-10-26 |
US20210401837A1 (en) | 2021-12-30 |
US20220202815A1 (en) | 2022-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201900163PA (en) | Macrocycle kinase inhibitors | |
SG11201811338VA (en) | A novel botulinum neurotoxin and its derivatives | |
SG11201900480YA (en) | Anti-tim-3 antibodies | |
SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
SG11201906763RA (en) | Pyrrolo [1,2-b] pyridazine derivatives | |
SG11201806322QA (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
SG11201909011PA (en) | Niraparib compositions | |
SG11201900844UA (en) | Amino pyrimidine ssao inhibitors | |
SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
SG11201407200TA (en) | Liquid formulation | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201806133UA (en) | Intermediates in the synthesis of eribulin and related methods of synthesis | |
SG11201806480UA (en) | Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer |